CYTARABINE STADA 50MG/ML (4G) VIAL

Description A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia especially acute non-lymphoblastic leukemia. Indication For the treatment of acute non-lymphocytic leukemia acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia. Mechanism of action Cytarabine acts through direct DNA damage and incorporation into DNA. Cytarabine is cytotoxic to a wide variety of proliferating mammalian cells in culture. It exhibits cell phase specificity primarily killing cells undergoing DNA synthesis (S-phase) and under certain conditions blocking the progression of cells from the G1 phase to the S-phase. Although the mechanism of action is not completely understood it appears that cytarabine acts through the inhibition of DNA polymerase. A limited but significant incorporation of cytarabine into both DNA and RNA has also been reported.